Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zenocutuzumab + afatinib
- Development stage
- Unknown
- Lead developer
- Merus
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Zenocutuzumab + afatinib is an investigational combination therapy comprised of zenocutuzumab, a bispecific IgG1 monoclonal antibody targeting HER2 and HER3, and afatinib, a small molecule irreversible inhibitor of EGFR and HER2 signals, both administered to treat advanced solid tumors with neuregulin 1 (NRG1) gene fusions. Zenocutuzumab blocks the dimerization of HER2:HER3 and prevents NRG1 binding to HER3, thereby inhibiting downstream PI3K-AKT-mTOR cell signaling and mediating antibody-dependent cellular cytotoxicity (ADCC)[1][4][6]. Afatinib simultaneously inhibits EGFR (ErbB1) and HER2 (ErbB2) signaling, providing complementary inhibition of the ErbB receptor family. Combined, the therapy aims to overcome resistance mechanisms and improve efficacy for tumors driven by NRG1 gene fusions. Clinical studies are investigating the combination in NRG1-positive, advanced non-small cell lung cancer (NSCLC) and other solid tumors[7].
- Brand names
- Bizengri + Gilotrif
- Other names
- zenocutuzumab + afatinib
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)ERBB3 (Erb-b2 receptor tyrosine kinase 3)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)
Beyond the preview
Go deeper on zenocutuzumab + afatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zenocutuzumab + afatinib.